Unlocking Global Markets: SaMD, AI, and Regulatory Fast-Tracks

This episode provides a comprehensive guide to navigating the complex global regulatory landscape for Software as a Medical Device (SaMD), with a special focus on AI-enabled technologies. We explore SaMD risk classifications in key markets like the US, EU, and Canada, discuss recent AI-specific guidance from bodies like the FDA (including the December 2024 updates and PCCPs) and MHRA (June 2024 updates), and highlight available fast-track options. We also offer practical strategies for a successful multi-country SaMD launch in 2025 and beyond. Key Questions: • How do SaMD risk classifications differ between the US FDA, EU MDR, and other global regions? • What are the latest AI medical device guidance updates for 2024 from the FDA and UK's MHRA? • How can a Predetermined Change Control Plan (PCCP) streamline AI SaMD updates in the US? • What impact does the EU AI Act have on SaMD, alongside MDR Rule 11? • Which fast-track options can accelerate SaMD market entry in major jurisdictions? • What are the key practical steps for developing a multi-country SaMD launch strategy for 2025? • How does global harmonization, led by IMDRF, affect SaMD regulations? • Why are cybersecurity and transparency crucial for modern SaMD approvals? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.